NASDAQ
CNCE

Concert Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Concert Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$5.6000
Today's High:
$5.9500
Open Price:
$5.8800
52W Low:
$2.57
52W High:
$7.37
Prev. Close:
$5.9100
Volume:
611215

Company Statistics

Market Cap.:
$0.278 billion
Book Value:
2.667
Revenue TTM:
$0.033 billion
Operating Margin TTM:
-274.6%
Gross Profit TTM:
$-0.055 billion
Gross Profit TTM:
$-0.055 billion
Profit Margin:
0%
Return on Assets TTM:
-34.4%
Return on Equity TTM:
-99.1%

Company Profile

Concert Pharmaceuticals Inc had its IPO on 2014-02-13 under the ticker symbol CNCE.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Concert Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of Concert Pharmaceuticals Inc opened at $5.88 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $5.6 - $5.95, and closed at $5.8.

This is a -1.86% slip from the previous day's closing price.

A total volume of 611,215 shares were traded at the close of the day’s session.

In the last one week, shares of Concert Pharmaceuticals Inc have slipped by -3.33%.

Concert Pharmaceuticals Inc's Key Ratios

Concert Pharmaceuticals Inc has a market cap of $0.278 billion, indicating a price to book ratio of 2.262 and a price to sales ratio of 8.53.

In the last 12-months Concert Pharmaceuticals Inc’s revenue was $0.033 billion with a gross profit of $-0.055 billion and an EBITDA of $-0.088 billion. The EBITDA ratio measures Concert Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Concert Pharmaceuticals Inc’s operating margin was -274.6% while its return on assets stood at -34.4% with a return of equity of -99.1%.

In Q2, Concert Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 23.5%.

Concert Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
0

Its diluted EPS in the last 12-months stands at $-2.71 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Concert Pharmaceuticals Inc’s profitability.

Concert Pharmaceuticals Inc stock is trading at a EV to sales ratio of 257.75 and a EV to EBITDA ratio of -1.24. Its price to sales ratio in the trailing 12-months stood at 8.53.

Concert Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Concert Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Concert Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Concert Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Concert Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Concert Pharmaceuticals Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$5.8
52-Week High
$7.37
52-Week Low
$2.57
Analyst Target Price
$17.2

Concert Pharmaceuticals Inc stock is currently trading at $5.8 per share. It touched a 52-week high of $7.37 and a 52-week low of $7.37. Analysts tracking the stock have a 12-month average target price of $17.2.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Concert Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Concert Pharmaceuticals Inc is CNCE

The IPO of Concert Pharmaceuticals Inc took place on 2014-02-13

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$24.5
-1.1
-4.3%
$2.51
0.06
+2.45%
$7.17
-0.27
-3.63%
$59.25
-1.41
-2.32%
$43.65
-1.61
-3.56%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing new small molecule drugs for the treatment of autoimmune diseases. The company is headquartered in Lexington, Massachusetts.

Address

65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, US